The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
Open accessAbstract
Objective: To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design: Comparative observational study using data collected from routine care. Setting: Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. Participants: 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. Interventions: Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). Main outcome measures: The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results: In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. Conclusions: Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Acute Respiratory Distress Syndrome: The Berlin Definition
(2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 8,731
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
Hernán, M. A., & Robins, J. M. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv254 · Cited by 3,115
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Lunceford, J. K., & Davidian, M. (2004) · Statistics in Medicine · doi:10.1002/sim.1903 · Cited by 1,674
Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review
Ye, Z., Zhang, Y., Wang, Y., Huang, Z., & Song, B. (2020) · European Radiology · doi:10.1007/s00330-020-06801-0 · Cited by 1,349
Clinical and virological data of the first cases of COVID-19 in Europe: a case series
Lescure, F.-X., Bouadma, L., Nguyen, D., Parisey, M., Wicky, P.-H., Behillil, S., Gaymard, A., Bouscambert-Duchamp, M., Donati, F., Le Hingrat, Q., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30200-0 · Cited by 1,092
Self-citationEfficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
Freund, Y., Lemachatti, N., Krastinova, E., Van Laer, M., Claessens, Y.-E., Avondo, A., Occelli, C., Feral-Pierssens, A.-L., Truchot, J., Ortega, M., et al. (2017) · JAMA · doi:10.1001/jama.2016.20329 · Cited by 708
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Giudicessi, J. R., Noseworthy, P. A., Friedman, P. A., & Ackerman, M. J. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.03.024 · Cited by 394
Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.4812 · Cited by 378
Race to find COVID-19 treatments accelerates
Kupferschmidt, K., & Cohen, J. (2020) · Science · doi:10.1126/science.367.6485.1412 · Cited by 378
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., et al. (2020) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12543 · Cited by 239
Yazdany, J., & Kim, A. H. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1334 · Cited by 236
Kim, A. H. J., Sparks, J. A., Liew, J. W., Putman, M. S., Berenbaum, F., Duarte-García, A., Graef, E. R., Korsten, P., Sattui, S. E., Sirotich, E., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1223 · Cited by 205
Hydroxychloroquine: A multifaceted treatment in lupus
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Le Guern, V., & Guettrot-Imbert, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.007 · Cited by 194
Self-citationCovid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence
Lenzer, J. (2020) · BMJ · doi:10.1136/bmj.m1335 · Cited by 114
Immunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Hernán, M. Á., Schisterman, E. F., & Hernández–Dı́az, S. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt283 · Cited by 38
Cited by
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022926 · Cited by 1,265
Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31180-6 · Cited by 1,200
RetractedGianfrancesco, M., Hyrich, K. L., Al-Adely, S., Carmona, L., Danila, M. I., Gossec, L., Izadi, Z., Jacobsohn, L., Katz, P., Lawson-Tovey, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217871 · Cited by 1,141
Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)
Umakanthan, S., Sahu, P., Ranade, A. V., Bukelo, M. M., Rao, J. S., Abrahao-Machado, L. F., Dahal, S., Kumar, H., & KV, D. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138234 · Cited by 717
Metadata
- Authors
- Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., Schlemmer, F., Matignon, M., Khellaf, M., Crickx, E., Terrier, B., Morbieu, C., Legendre, P., Dang, J., Schoindre, Y., Pawlotsky, J.-M., Michel, M., Perrodeau, E., Carlier, N., Roche, N., de Lastours, V., Ourghanlian, C., Kerneis, S., Ménager, P., Mouthon, L., Audureau, E., Ravaud, P., Godeau, B., Gallien, S., & Costedoat-Chalumeau, N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-05-14
- Volume
- 369
- Pages
- m1844
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3025972894
- Cited by
- 566
- References
- 30
- FWCI
- 16.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.